MD Anderson researchers have identified potential biomarkers for the response of high-grade serous ovarian cancers (HGSC) to surgical resection alone or to chemotherapy before surgery, providing new avenues to explore for improving ovarian cancer treatment.
Their ovarian cancer research findings, in collaboration with Inova Health System, were published today in Cell Reports.
HGSC accounts for nearly 90% of ovarian cancer...
